Venn Life Sciences Holdings PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Venn Life Sciences Holdings PLC announces acquisition of Belfast based CRO
Venn Life Sciences Holdings PLC:Says it has acquired a Clinical Research Organisation (CRO) business based in Northern Ireland, for a total maximum consideration of 670,000 pounds.Says it has acquired the entire issued share capital of Medevol Limited (Medevol) for an initial cash consideration of 70,000 pounds, to be satisfied through the company's existing cash resources.Says there will be additional deferred consideration payable of up to a maximum of 600,000 pounds over the next two years should Medevol hit certain financial targets relating to the business's annualised profit before tax.Says any additional consideration will be satisfied as to one half in cash and one half in Venn shares.
Latest Developments for Venn Life Sciences Holdings PLC
- Venn Life Sciences Holdings Plc announces placing to raise 1 mln pounds
- Venn Life Sciences Holdings PLC Announces Launch of Innovation Division and Co-Development Initiative
- Venn Life Sciences Holdings PLC Announces Senior Management Appointments
- Venn Life Sciences Holdings PLC Establishes Joint Venture in Russia
- Share this
- Digg this